- Tytuł:
- EE514 A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Third- or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)
- Autorzy:
- Źródło:
- In Value in Health June 2023 26(6) Supplement:S153-S153
Czasopismo naukowe